Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimasertib versus dacarbazine in previously untreated NRAS-mutant advanced cutaneous melanoma
NL-OMON41477Phase 2Active, not recruiting
- Sponsor
- Merck Serono
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cutaneous melanoma (CM) comparing Pimasertib with Dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Apr 2013; status: active, not recruiting.
02
Drugs
pimasertibdacarbazine
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON41477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41477.